Dr. Jaime Luis Torres Ii, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 6279 N Lecanto Hwy, Beverly Hills, FL 34465 Phone: 352-522-0094 Fax: 352-522-0098 |
Dr. Odelsa Diaz Andres, M.D General Practice Medicare: Accepting Medicare Assignments Practice Location: 6279 N Lecanto Hwy, Beverly Hills, FL 34465 Phone: 352-522-0094 Fax: 352-522-0098 |
Dr. Juan Galvan, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 6279 N Lecanto Hwy, Beverly Hills, FL 34465 Phone: 352-522-0094 Fax: 352-522-0098 |
News Archive
Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.
Magnetic fields generated by microscopic devices implanted into the brain may be able to modulate brain-cell activity and reduce symptoms of several neurological disorders.
Results of a new study reported this week by David Moorman of the University of Massachusetts Amherst and Gary Aston-Jones of Rutgers University suggest that adjusting behavior based on previous events involves an unexpected mix of neurons working together in the brain's prefrontal cortex.
Addiction is a brain disease that destroys lives, devastates families and tears at the very fabric of society. Effective prevention and treatment of addiction requires a clear understanding of the complex brain mechanisms that underlie addictive behaviors, and research has provided a fascinating view of how substance abuse hijacks neuronal circuits involved in reward and motivation and causes profound and persistent changes in behavior.
HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.
› Verified 2 days ago